RBC Capital Upgrades Medtronic, Inc. (MDT) to Outperform

Barclays Upgrades Medtronic, Inc. (MDT) to Overweight

Barclays upgraded Medtronic, Inc. (NYSE: MDT) from Equalweight to Overweight with a price target of $73.00 (from $67.00).

For an analyst ratings summary and ratings history on Medtronic, Inc. click here. For more ratings news on Medtronic, Inc. click here.

Shares of Medtronic, Inc. closed at $61.58 yesterday.

BTIG Upgrades Medtronic, Inc. (MDT) to Buy

BTIG upgraded Medtronic, Inc. (NYSE: MDT) from Neutral to Buy with a price target of $73.00. The change follows news it plans to acquire Covidien (NYSE: COV).

Analyst Sean Lavin said,... More

Morgan Stanley Upgrades Medtronic, Inc. (MDT) to Overweight

Morgan Stanley upgraded Medtronic, Inc. (NYSE: MDT) from Equalweight to Overweight.

For an analyst ratings summary and ratings history on Medtronic, Inc. click here. For more ratings news on Medtronic, Inc. click here.

Shares of Medtronic, Inc. closed at $60.03 yesterday.

Needham & Company Comments on Sector Implications Amid Medtronic (MDT)/Covidien (COV) Megadeal

Needham & Company analyst Mike Matson comments on the sector implications amid Medtronic's (NYSE: MDT) $42.9 billion deal to acquire Covidien (NYSE: COV).

The analyst said while the media is likely to focus on the tax inversion angle, which is certainly playing a role, they... More

William Blair Upgrades Medtronic, Inc. (MDT) to Outperform

William Blair upgraded Medtronic, Inc. (NYSE: MDT) from Market Perform to Outperform.

For an analyst ratings summary and ratings history on Medtronic, Inc. click here. For more ratings news on Medtronic, Inc. click here.

Shares of Medtronic, Inc. closed at $60.70 yesterday.

UPDATE: JPMorgan Upgrades Medtronic, Inc. (MDT) to Overweight

(Updated - June 16, 2014 11:35 AM EDT)

JPMorgan upgraded Medtronic, Inc. (NYSE: MDT) from Neutral to Overweight with a price target of $78.00 (from $64.00). The upgrade follows Medtronics agreement to acquire Covidien (NYSE: COV).

Analyst Michael... More

Sanofi (SNY), Medtronic (MDT) Enter Dabetes Collaboration

Sanofi (NYSE: SNY) and Medtronic, Inc. (NYSE: MDT) announced that they have signed a memorandum of understanding to enter into a global strategic alliance in diabetes, aimed at improving patient experience and outcomes for people with diabetes around the world. The alliance will initially focus on two key priorities: the development of drug-device combinations and delivery of care management services to improve adherence, simplify insulin treatment, and help people with diabetes better manage their condition.

The alliance will be structured as an open-innovation model, leveraging the... More

Medtronic (MDT) to Acquire Covidien (COV) in $42.9B Deal

Medtronic, Inc. (NYSE: MDT), a global leader in medical technology, services and solutions, and Covidien plc (NYSE: COV), a global healthcare technology and medical supplies provider, today announced that they have entered into a definitive agreement under which Medtronic has agreed to acquire Covidien in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9 billion, based on Medtronic`s closing stock price of $60.70 per share on June 13, 2014.

Once the transaction is completed, Medtronic will have significantly advanced its position as the world`s premier... More

Medtronic (MDT) in Advanced Talks to Acquire Covidien (COV) - WSJ

Medtronic (NYSE: MDT) is in advanced talks to acquire Covidien (NYSE: COV) for more than $40 billion, the Wall Street Journal reported Saturday citing people familiar with the matter. The deal price suggests a premium of at... More